Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557372 · ClinicalTrials.gov registry record · NA
Mathematical Model-Adapted Radiation In Glioblastoma
A NA study of Recurrent Glioblastoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT03557372 is a NA study of Recurrent Glioblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03557372, a NA study of Recurrent Glioblastoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: \- Re-irradiation for glioblastoma using a novel Mathematical Model-Adapted Radiation Fractionation Schedule
Conditions Studied
Interventions
- RADIATION Mathematical Model-Adapted Radiation Fractionation Schedule
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2022-11-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557372
The ClinicalTrials.gov registry entry for NCT03557372 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (80% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Mathematical Model-Adapted Radiation Fractionation Schedule is the first listed.
NCT03557372 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03557372 about?
NCT03557372 is a clinical study titled "Mathematical Model-Adapted Radiation In Glioblastoma". This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: \- Re-i...
What is the current status of trial NCT03557372?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-11-12. Estimated completion is 2022-11-09.
What conditions does trial NCT03557372 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT03557372?
The interventions under investigation include: Mathematical Model-Adapted Radiation Fractionation Schedule (RADIATION).
Who is sponsoring clinical trial NCT03557372?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03557372 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
RECRUITING · NA
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.